Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

By LabMedica International staff writers
Posted on 07 Jul 2025

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. More...

Unlike osteoarthritis, which is caused by wear and tear, RA can strike suddenly and is most common in people aged 40-60. The disease is often difficult to treat due to the variation in patients' responses to therapies, with biological therapies offering the best treatment options. However, there is no diagnostic test that can predict which therapy will work for a specific patient. As a result, many patients endure multiple rounds of failed treatments, each carrying the risk of severe side effects and infections due to the suppression of the immune system. New research has identified a way to predict which therapies are most likely to succeed for individual patients, thereby minimizing ineffective treatments and improving patient outcomes.

This breakthrough solution was developed by scientists at Queen Mary University of London (London, UK) by combining deep molecular phenotyping and machine learning to predict patient responses to biological therapies for RA. By extracting RNA from a biopsy taken from an affected joint, they measure the activity of 524 specific genes. This data is then analyzed using machine learning models designed to predict the likelihood of success for three main biological therapies: etanercept, tocilizumab, and rituximab. The approach aims to enable clinicians to select the most effective treatment from the start, reducing the chances of adverse effects and unnecessary treatments.

The research was tested in clinical trials, with results showing that the predictive models accurately forecasted patient responses for 79%-85% of patients. Published in Nature Communications, the findings suggest that this method could significantly improve patient well-being by guiding clinicians toward the most suitable therapy faster. The researchers are in discussions with commercial partners to help bring this predictive tool to clinical practice and are conducting large, randomized controlled trials to further refine the technology. With a clinical trial underway, the team is on course to be the first to introduce a predictive test into a real-world medical setting. Their new approach could revolutionize the way RA treatments are personalized, providing patients with better outcomes and a more efficient healthcare system.  

“This innovation could have major benefits for patients and healthcare providers alike,” said Prof Costantino Pitzalis, Professor of Rheumatology at Queen Mary University of London. “Prescribing the right treatment first time would reduce patient suffering and make our healthcare system more efficient.”

Related Links:
Queen Mary University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Drug Testing Assays
Atellica DT 250 Analyzer
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.